Marijn E Dekkers
CIK 1216068 · Chief Executive Officer · last filed 2024-08-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TMO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
41 FARNSWORTH STREET
BOSTON, MA 02210
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Director | 5,901,844 | $0.01 | $37.2K | -$2.27M | 8 | 2024-06-14 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 444,609 | $44.96 | $19.99M | -$6.89M | 5 | 2024-06-07 |
| QSI | Director | 650,000 | $1.65 | $1.07M | $0 | 2 | 2022-05-13 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | — | $18.07 | — | $0 | 1 | 2021-06-14 |
| QTRX | Director | 11,031 | $2.93 | $32.3K | -$4.63M | 10 | 2021-06-08 |
| GE | Director | 8,226 | $294.43 | $2.42M | $1.16M | 25 | 2018-04-02 |
| TMO | Chief Executive Officer | 102,814 | $693.65 | $71.32M | -$123.13M | 29 | 2009-08-18 |
| BIIB | Director | 6,595 | $251.22 | $1.66M | $0 | 3 | 2009-06-05 |
Recent Filings · Page 7 of 9
87 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-08-07 | TMO | Mixed | −100,000 | -$10.72M | EDGAR |
| 2008-06-23 | BIIB | Grant (A) | +2,050 | $0 | EDGAR |
| 2008-03-28 | TMO | Grant (A) | — | $0 | EDGAR |
| 2008-03-07 | TMO | Grant (A) | — | $0 | EDGAR |
| 2008-03-03 | TMO | Mixed | +69,352 | -$1.75M | EDGAR |
| 2008-01-08 | TMO | Mixed | +4,403 | -$34.0K | EDGAR |
| 2007-11-29 | TMO | Sell (S) | −10,700 | -$611.0K | EDGAR |
| 2007-11-29 | TMO | Mixed | +10,700 | -$4.33M | EDGAR |
| 2007-11-27 | TMO | Sell (S) | −2,900 | -$165.7K | EDGAR |
| 2007-11-27 | TMO | Mixed | +2,900 | -$4.78M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.